Abstract
Hypertension poses serious health risks for blacks because this population presents with earlier onset and more severe forms of the disease than do nonblacks. Although diuretics are the cornerstone of antihypertensive therapy In the black population, investigators have expressed concern about adverse metabolic effects, such as hypokalemia, produced by the high doses of diuretics traditionally prescribed for blacks. Recent evidence suggests that black patients may respond equally well to the new generation of cardioselective beta-blockers and angiotensin-converting enzyme inhibitors, particularly when these agents are used together with a diuretic. A new low-dose multimechanism agent that combines the cardioselective beta-blocker bisoprolol fumarate with hydrochlorothiazide, a benzothiazine diuretic, is now available for first-line therapy for hypertension. Results of two US multicenter trials--including a subset analysis of black patients--indicate that the once-daily agent is highly effective in reducing diastolic and systolic blood pressure throughout a 24-hour period in both black and nonblack patients. The agent is well tolerated in blacks and non-blacks and has a side-effect profile comparable to placebo. Because of its efficacy and safety in black patients, bisoprolol fumarate/-hydrochlorothiazide is an appropriate therapeutic option for first-line therapy of hypertension in the black population.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cook C. A. Pathophysiologic and pharmacotherapy considerations in the management of the black hypertensive patient. Am Heart J. 1988 Jul;116(1 Pt 2):288–295. doi: 10.1016/0002-8703(88)90102-0. [DOI] [PubMed] [Google Scholar]
- Croog S. H., Kong B. W., Levine S., Weir M. R., Baume R. M., Saunders E. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group. Arch Intern Med. 1990 Aug;150(8):1733–1741. doi: 10.1001/archinte.150.8.1733. [DOI] [PubMed] [Google Scholar]
- Ferdinand K. C. New Joint National Committee recommendations as they affect black hypertensive patients. J Natl Med Assoc. 1989 Apr;81 (Suppl):31–40. [PMC free article] [PubMed] [Google Scholar]
- Fogari R., Zoppi A., Pasotti C., Poletti L., Tettamanti F., Maiwald C. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension. Int J Clin Pharmacol Ther Toxicol. 1988 Dec;26(12):597–604. [PubMed] [Google Scholar]
- Kaplan N. M. The case for low dose diuretic therapy. Am J Hypertens. 1991 Dec;4(12 Pt 1):970–971. doi: 10.1093/ajh/4.12.970. [DOI] [PubMed] [Google Scholar]
- Lewin A. J., Lueg M. C., Targum S., Cardenas P. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. Clin Cardiol. 1993 Oct;16(10):732–736. doi: 10.1002/clc.4960161009. [DOI] [PubMed] [Google Scholar]
- Neutel J. M., Smith D. H., Ram C. V., Lefkowitz M. P., Kazempour M. K., Weber M. A. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol. 1993 Jul 1;72(1):41–46. doi: 10.1016/0002-9149(93)90216-y. [DOI] [PubMed] [Google Scholar]
- Saunders E. Drug treatment considerations for the hypertensive black patient. J Fam Pract. 1988 Jun;26(6):659–664. [PubMed] [Google Scholar]
- Saunders E., Weir M. R., Kong B. W., Hollifield J., Gray J., Vertes V., Sowers J. R., Zemel M. B., Curry C., Schoenberger J. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990 Aug;150(8):1707–1713. [PubMed] [Google Scholar]
- Schaer D. H., Buff L. A., Katz R. J. Sustained antianginal efficacy of transdermal nitroglycerin patches using an overnight 10-hour nitrate-free interval. Am J Cardiol. 1988 Jan 1;61(1):46–50. doi: 10.1016/0002-9149(88)91302-1. [DOI] [PubMed] [Google Scholar]
- The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) Arch Intern Med. 1993 Jan 25;153(2):154–183. [PubMed] [Google Scholar]
- Zachariah P. K., Messerli F. H., Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. Clin Ther. 1993 Sep-Oct;15(5):779–787. [PubMed] [Google Scholar]